Lipid degradation promotes prostate cancer cell survival
- PMID: 28415728
- PMCID: PMC5503531
- DOI: 10.18632/oncotarget.16123
Lipid degradation promotes prostate cancer cell survival
Abstract
Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.
Keywords: ECI2; androgen receptor; cell cycle; lipid degradation; metabolism.
Conflict of interest statement
None.
Figures
Similar articles
-
The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression.Nat Commun. 2024 Aug 21;15(1):7184. doi: 10.1038/s41467-024-51489-1. Nat Commun. 2024. PMID: 39169021 Free PMC article.
-
HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.Sci Rep. 2020 Sep 1;10(1):14365. doi: 10.1038/s41598-020-71427-7. Sci Rep. 2020. PMID: 32873863 Free PMC article.
-
Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.Mol Cancer Res. 2019 May;17(5):1166-1179. doi: 10.1158/1541-7786.MCR-18-1147. Epub 2019 Feb 26. Mol Cancer Res. 2019. PMID: 30808729
-
Mechanisms of prostate cancer cell survival after inhibition of AR expression.J Cell Biochem. 2009 Feb 15;106(3):363-71. doi: 10.1002/jcb.22022. J Cell Biochem. 2009. PMID: 19115258 Review.
-
Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.Cell Cycle. 2007 Mar 15;6(6):647-51. doi: 10.4161/cc.6.6.4028. Epub 2007 Mar 21. Cell Cycle. 2007. PMID: 17387277 Review.
Cited by
-
Role of the Sterol Regulatory Element Binding Protein Pathway in Tumorigenesis.Front Oncol. 2020 Sep 8;10:1788. doi: 10.3389/fonc.2020.01788. eCollection 2020. Front Oncol. 2020. PMID: 33014877 Free PMC article. Review.
-
HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.Oncol Lett. 2019 Jan;17(1):1094-1100. doi: 10.3892/ol.2018.9677. Epub 2018 Nov 8. Oncol Lett. 2019. PMID: 30655870 Free PMC article.
-
Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo.iScience. 2023 May 19;26(6):106899. doi: 10.1016/j.isci.2023.106899. eCollection 2023 Jun 16. iScience. 2023. PMID: 37305702 Free PMC article.
-
The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression.Oncogene. 2019 Jan;38(3):421-444. doi: 10.1038/s41388-018-0450-6. Epub 2018 Aug 17. Oncogene. 2019. PMID: 30120411 Free PMC article.
-
Expression status and prognostic value of autophagy-related lncRNAs in prostate cancer.Cell Cycle. 2022 Aug;21(16):1684-1696. doi: 10.1080/15384101.2022.2065149. Epub 2022 Apr 24. Cell Cycle. 2022. PMID: 35414328 Free PMC article.
References
-
- Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature reviews Cancer. 2014;14:187–198. - PubMed
-
- Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer cell. 2013;23:35–47. - PubMed
-
- Geisbrecht BV, Zhang D, Schulz H, Gould SJ. Characterization of PECI, a novel monofunctional Delta(3), Delta(2)-enoyl-CoA isomerase of mammalian peroxisomes. The Journal of biological chemistry. 1999;274:21797–21803. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
